Original
Higher systemic antibiotic consumption in a population of South Korea (2008 – 2009)
Hyun Soon Sohn, Ock Hee Oh, Jin-Won Kwon and Young Sook Lee
Price
42.00 $
Volume 51 p. 585 - 592
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 7/2013 (585-592)
Higher systemic antibiotic consumption in a population of South Korea (2008 – 2009)
Hyun Soon Sohn1, Ock Hee Oh2, Jin-Won Kwon3 and Young Sook Lee4
1College of Pharmacy, Sookmyung Women’s University, 2FirstDis Korea, Seoul, 3College of Pharmacy, Kyungpook National University, Daegu, and 4College of Pharmacy, Keimyung University, Daegu, Republic of Korea
This study was conducted to investigate overall systemic antibiotic consumption levels and specific patterns using standardized Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. National Health Insurance claims data during 2008 and 2009 was used. Antibiotic prescription data was classified using the ATC system and converted into DDD. Consumption figures were presented as the number of DDD per 1,000 inhabitants per day (DID). Detailed information on indications and seasonal variations, age and institutional determinants on antibiotic consumption were also explored. Total consumption was slightly increased from 24.3 to 25.2 DID in 2009 compared to 2008. The most frequently prescribed antibiotic was amoxicillin/clavulanic acid (5.1 and 5.2 DID, in 2008 and 2009, respectively), followed by cefaclor (3.0 and 3.3 DID) and amoxicillin (3.3 and 3.2 DID). Respiratory system diseases were the main causes of antimicrobial prescription (47.3%) and acute forms of bronchitis, tonsillitis and sinusitis were the most common diseases. There were typical seasonal fluctuations with heightened winter peaks. Consumption figures under 5 years of age (41.6 and 43.3 DID) were even higher than figures in aged 65 – 80 (36.2 and 39.1 DID). Antibiotic consumption in South Korea remained high compared with other OECD countries. Efforts to increase prudent antibiotic use, especially for upper respiratory system infections and for younger children, should be made to decrease antibiotic use.Correspondence to:
Young Sook Lee, PharmD
College of Pharmacy, Keimyung University
1095 Dalgubeol-daero
Daegu, 704-710, Republic of Korea
Email: [email protected]
Original
What are the patient factors affecting repetitive use of injectable pain relievers in outpatient care settings?
Juyeun Lee, Sunmee Jang, Euna Han, Eun-Ju Lee, Yun Jung Choi, and Hyun Soon Sohn
Price
42.00 $
Volume 52 p. 202 - 208
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 52 – No. 3/2014 (202-208)
What are the patient factors affecting repetitive use of injectable pain relievers in outpatient care settings?
Juyeun Lee1, Sunmee Jang2, Euna Han3, Eun-Ju Lee4, Yun Jung Choi1, and Hyun Soon Sohn5
1College of Pharmacy, Hanyang University, Ansan, 2College of Pharmacy, Inje University, Gimhae, 3College of Pharmacy, Yonsei University, Incheon, 4Graduate School of Public Health, Seoul National University, Seoul, and 5College of Pharmacy, Ajou University, Suwon, South Korea
Targeting repeated injection users with education interventions aimed at highlighting the extent of their current use and increasing awareness of the oral preparation options may reduce unnecessary injection use. The aim of this retrospective observational study was to investigate the patient factors related to repeated use of injection formulation analgesics in patients with musculoskeletal disorders who were frequent users of ambulatory healthcare services. Population-based national health insurance claims data for the time period July 2011 – December 2011 were analyzed. Patients aged 18 – 80 years with a musculoskeletal disorder, attended ambulatory healthcare settings > 25 times, and were prescribed pain relievers such as non-steroidal anti-inflammatory drugs and narcotic analgesics in an oral formulation for ≥ 14 days or in an injection formulation ≥ 3 times during the study period were included in the study. There were 742,675 repeated systemic analgesic users, and 64.1% (n = 476,021) of these patients were injection users. The average use of injections per patient during the 6-month period was 8.3. Tramadol was the most frequently prescribed medication for injection, followed by diclofenac, piroxicam, and ketorolac. Statistical analyses showed significant correlations between prevalent injection formulation use and patient factors such as gender, age, area of residence, days of healthcare utilization, number of healthcare centers visited, type of healthcare center visited, total medical expenditure, and total out-of-pocket expenditure. These factors could possibly be used to determine the target population for educational interventions aimed at changing behavior relating to the preference for injectable formulations.Correspondence to:
Hyun Soon Sohn, PhD
College of Pharmacy, Ajou University
206 Worldcup-ro, Yeongtong-gu,
Suwon-si, Gyeonggi-do, 443-749, South Korea
Email: [email protected]
Original
Patient response to insurer-led intervention for medication adherence – a pilot study based on claims data in Korea
Hyun Soon Sohn, Sunmee Jang, Ju-Yeun Lee, and Euna Han
Price
42.00 $
Volume 54 p. 28 - 35
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 54 – No. 1/2016 (28-35)
Patient response to insurer-led intervention for medication adherence – a pilot study based on claims data in Korea
Hyun Soon Sohn1, Sunmee Jang2, Ju-Yeun Lee3, and Euna Han4
1Graduate School of Clinical Pharmacy, CHA University, Gyeonggi-do, 2College of Pharmacy, Gachon University, Incheon, 3College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do, and 4College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea
Objective: This study was designed to investigate patient responses to a medication counseling intervention program piloted by the National Health Insurance Service (NHIS), the national health insurer in Korea, to improve medication management in patients with hypertension, hyperlipidemia, or diabetes. Methods and materials: Interventions were conducted from July to September 2013 through direct mailing followed by two telephone-initiated counseling sessions for the medication discontinuation group (< 80% medication possession ratio (MPR) and ≥ 2 months of discontinuation) and the medication over-possession group (≥ 150% MPR). The telephone intervention was applied through two models: model 1 (counseling by NHIS staff only) and model 2 (counseling by NHIS staff with contract-based working pharmacists in community pharmacies). Multivariate logistic regression analysis was performed to identify factors affecting favorable responses of patients to the telephone-initiated intervention. Patient responses to the telephone-initiated intervention were evaluated by a counselor. Results: In all, 891 patients were counseled via telephone. Patient responses to the telephone-initiated intervention were favorable in 57.6%, neutral in 17.4% and not favorable in 24.9% overall. Counseling by NHIS staff together with pharmacists (model 2) produced more favorable responses from patients than counseling by NHIS staff alone (model 1) (OR 2.73, 95% CI 1.97 – 3.77). Conclusion: Our findings of favorable responses to interventions support a personalized approach by the NHIS to improve patient behavior for medication adherence.Correspondence to:
Euna Han, PhD, Associate Professor
College of Pharmacy & Yonsei Institute of
Pharmaceutical Research, Yonsei University
162-1 Songdo-Dong, Yeonsu-Gu, Incheon, South Korea
Email: [email protected]
Original
Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review
Hyun Soon Sohn, Hyunah Kim, Im-Sook Song, Eunjeong Lim, Mihwa Kwon, Ji-Hye Ha, and Jin-Won Kwon
Price
42.00 $
Volume 53 p. 621 - 634
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 53 – No. 8/2015 (621-634)
Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review
Hyun Soon Sohn1*, Hyunah Kim2*, Im-Sook Song3, Eunjeong Lim3, Mihwa Kwon3, Ji-Hye Ha4, and Jin-Won Kwon3
1Graduate School of Clinical Pharmacy, CHA University, Gyeonggi-do, 2College of Pharmacy, Sookmyung Women’s University, Seoul, 3College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, and 4Clinical Research Division, National Institute of Food and Drug Safety Evaluation (NIFDS), Chungcheongbuk-do, South Korea
This study was conducted to provide a narrative overview of interactions between smoking and drug effectiveness/ pharmacokinetics. Database searches were performed to identify review articles published prior to March 10, 2013. Eligible articles reporting altered pharmacokinetic profiles, drug response, or adverse drug effects due to drug-smoking interactions were selected. Information on mechanism of action and clinical effects from the selected articles (n = 83) were summarized by therapeutic drug class. For cardiovascular drugs, smoking effects were variable. Smoking reduced aspirin response but increased clopidogrel response by increasing active metabolites. Warfarin, which has a narrow therapeutic range, required dosage adjustment in smokers due to its rapid clearance. Smoking is a risk factor for respiratory disease, leading to a lower response to corticosteroid and requiring increased doses or additional drugs. Higher doses of theophylline and some antipsychotics, which are mainly metabolized by CYP1A2, are required to reach an optimal plasma concentration in smokers. Smoking is also a risk factor for cancer, especially for lung cancer. Erlotinib or gefitinib are epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for lung cancer and showed lower anticancer effects in smokers. This summary of the interactions between smoking and drug pharmacological properties will aid healthcare professionals in providing patients with appropriate drug therapies, and emphasizes the need for considering smoking status as a patient factor in the clinical setting.
*Sohn HS and Kim H equally contributed as co-first authors.Correspondence to:
Jin-Won Kwon, MPH, PhD
College of Pharmacy and Research Institute of Pharmaceutical Sciences
Kyungpook National University
80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
Email: [email protected]
Original
Prescribed drugs and polypharmacy in healthcare service users in South Korea: an analysis based on National Health Insurance Claims data
Hae-Young Park, Hyun-Nam Ryu, Mi Kyong Shim, Hyun Soon Sohn, and Jin-Won Kwon
Price
42.00 $
Volume 54 p. 369 - 377
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 54 – No. 5/2016 (369-377)
Prescribed drugs and polypharmacy in healthcare service users in South Korea: an analysis based on National Health Insurance Claims data
Hae-Young Park1, Hyun-Nam Ryu2, Mi Kyong Shim3, Hyun Soon Sohn3, and Jin-Won Kwon1
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, 2College of Natural Science, Kyungpook National University, Daegu, and 3Graduate School of Clinical Pharmacy, CHA University, Gyeonggi, South Korea
Objective: This study was conducted to analyze and compare the exposure to individually prescribed drugs and the prevalence of polypharmacy according to age group and concomitant disease in South Korea. Methods: The use of prescribed drugs was evaluated according to average numbers of prescription drugs used daily during a year or month, using the Korean Health Insurance Claims Database, which is representative of over 90% of citizens, in 2010 and 2011. The use of prescribed drugs was also analyzed according to concomitant diseases and age. Polypharmacy was defined as the use of 5 or more drugs daily during a specific observation period, and proportions of polypharmacy users were calculated according to comorbidity and age group. Results: The annual average numbers of daily used prescription drugs in 2010 and 2011 were 0.3 (SD = 0.5), 0.4 (SD = 0.7), 1.2 (SD = 1.5), and 2.3 (SD = 2.0) for people aged < 20 years, 20 – 49 years, 50 – 64 years, and ≥ 65 years, respectively. Proportions of individuals demonstrating polypharmacy increased with age and were 9.5% and 44.1% for elderly individuals in the year- and month-based analyses, respectively. The annual average number of daily medications used increased by ~ 2 drugs in the concomitant disease group, and the higher mortality group used a higher number of prescribed drugs than the lower mortality group. Conclusions: The results highlight the elevated burden of multi-medication in elderly patients, and the study found that prescribed drug use increased with age and the number of concomitant diseases.Correspondence to:
Jin-Won Kwon, MPH, PhD
College of Pharmacy and Research Institute of Pharmaceutical Sciences
Kyungpook National University
80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
or
Hyun Soon Sohn, PhD
Graduate School of Clinical Pharmacy
CHA University
335 Pankoro, Bundanggu, Sungnamsi,
Gyeonggi 487-010, South Korea
Email: [email protected] or [email protected]
Original
Real-world prescribing and switching patterns of non-calcium containing phosphate binders in dialysis patients in South Korea
Jong Joo Kim, Myeong Gyu Kim, Sung Cheol Park, Jinseub Hwang, and Hyun Soon Sohn
Price
42.00 $
Volume 58 (2020) p. 166 - 173
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 58 – No. 3/2020 (166-173)
Real-world prescribing and switching patterns of non-calcium containing phosphate binders in dialysis patients in South Korea
Jong Joo Kim1*, Myeong Gyu Kim2*, Sung Cheol Park3, Jinseub Hwang3, and Hyun Soon Sohn4
1Pharmaceutical Information Research Institute, 2Graduate School of Clinical Pharmacy, CHA University, Gyeonggi-do, 3College of Natural Science, Daegu University, Gyeongsangbuk-do, and 4College of Pharmacy, CHA University, Gyeonggi-do, South Korea
Objective: Non-calcium containing phosphate binders (non-CPBs) are useful for the treatment of hyperphosphatemia without a concern of hypercalcemia in patients undergoing dialysis. However, due to their relatively high cost, prescribing non-CPBs is restricted in South Korea. This study was conducted to investigate prescribing patterns, especially switching between CPBs and non-CPBs, in dialysis patients in a real-world setting.
Materials and methods: This is an observational study using the National Health Insurance Service claim data. The study population included patients who initiated dialysis between July 2012 and June 2013 and were prescribed phosphate binders at least once during the observation period (2012 – 2016) (n = 10,073). Medication costs and prescribing patterns including switching of phosphate binders were investigated.
Results: Compared with the first year of dialysis, the costs of phosphate binders more than doubled during the 4th year of dialysis (from US$ 28.4 to US$ 60.1), largely due to an increase in the cost of non-CPBs (from US$ 117.5 to US$ 237.8). Many patients continued to change drugs between CPBs and non-CPBs. The continuous prescription period of CPBs was shortened each time a drug was changed. A total of 551 patients (13.4%) changed their medication three times between CPBs and non-CPBs.
Conclusion: Over time on dialysis, use of non-CPB increased and medication costs increased accordingly. Many patients continued to change drugs between CPBs and non-CPBs due to the restricted criteria of the health insurance. Further outcome research is necessary to evaluate the appropriateness of the clinical practice in which CPBs and non-CPBs are alternately used.
*These authors contributed equally to this work.Correspondence to:
Hyun Soon Sohn, PhD
College of Pharmacy, CHA University
Gyeonggi-do,
13488 South Korea
Email: [email protected]
